Season 1, Episode 1
Inside Pearl AI: Capabilities, Market Position, and What’s Next
In this episode, we explore Pearl AI and what makes it one of the most talked-about platforms in dental technology right now.
Key takeaways
- Pearl is a radiologic AI platform: it reads X-rays and flags pathologies earlier and more often than the human eye.
- Where Pearl sits in the market compared with other dental AI tools.
- Capabilities and use cases many practices do not realize already exist.
- Where AI adoption across DSOs and private practices may be heading next.
Transcript
Read the full transcript
Transcript generated automatically and lightly edited. Speaker labels may occasionally be off.
Brian Colao: Welcome to the DSO Technology Show. I'm Brian Colao, Director of Dykema's DSO Industry Group. I'm here with my co-host, Matt McGaw. And our very special guest today is McKenzie Fagan, VP of Enterprise Sales at Pearl AI. And it's one of my favorite topics. I've said this over and over again, Matt, diagnostic AI is the single biggest advancement in the history of the dental industry. I know how, you know, broad that statement is or how
McKenzie Fagan: Mm-hmm.
Brian Colao: ... that statement is, but I really, really believe it. We're really honored to be able to talk about it today. And McKenzie thanks for being here.
McKenzie Fagan: Great to be here. Thanks for having me.
Brian Colao: So let's kinda dive right in here, and I always start with, look, you know, I've encouraged everybody to really understand and take the time to research diagnostic AI. I understand, though, some people that see this might have been busy. It might be difficult for them. Maybe they wanna learn about it. They haven't had the time. So let's start there, even though I know Pearl's been around for a while. It's got FDA clearances, all kinds of stuff. But just assume maybe somebody watching this has no idea what diagnostic AI is, and can you take us through that for a second?
McKenzie Fagan: Absolutely. So Pearl is a radiologic AI platform. The best way to think about it is Pearl looks at your X-rays and is able to find and detect pathologies on those X-rays earlier and often than the human eye can. I think the best analogy or way to understand it is doctors look at your X-rays to determine what your treatment plan is going to be. Pearl acts like spellcheck, where every single time your doctor looks at their X-rays, Pearl is there as a second opinion or a second set of eyes to ensure that if there's early stage pathologies, nothing goes missed, or even helps you as a patient understands for the first time your X-rays now in color. You can actually see and understand yourself what's going on in your mouth.
Brian Colao: Right. I actually, you know, I wanted you to explain this certainly, but I've had some experience with this. I mean, we now have my famous trip to the dentist. They had a camera crew follow me. I think, you know, tens of thousands of people have viewed it. But what it's like from the patient experience is you're sitting in a chair and before, because I've been going to the dentist for like 50 years, like previously, there'd be this black and white thing up there, I know, and you'd look at it, and the dentist would just explain it to you. Like, "I see a cavity there," and you would have, I mean, at least if you're me, you had no idea what they were talking about, if it's true or not. You hope you have a good dentist and you just can trust them and that's it. But I, I could not, in any way, interpret anything that was going on my X-ray. But since I've had the experience of utilizing Pearl AI as a patient, all of a sudden, a pink dot shows up there. And from the standpoint of the patient sitting in the chair, you see a pink up there, and I want you to talk a little bit about this, but it kinda overlays the X-ray and then the doctor will explain, but now you've got context sort of for what's going on.
McKenzie Fagan: Yeah, absolutely. And where it becomes really interesting too is when you compare historical images. Maybe your doctor tells you that you have an early stage cavity, but don't feel it. There's no pain. You don't really understand why you need to do anything about it, so you leave it as a watch tooth and you don't treat it. Well, you come back six months later or maybe even a year later and take X-rays again, and now you're able to see with Pearl that used to be a really small pink dot. Now it's a really big pink dot and we've got a significant problem. And this becomes a lot more fun where Pearl will actually analyze all of your historical or your previous X-rays that were taken so you don't have to wait those six months for it to become a problem. If you're using Pearl, you can open up your images, look at your images that were taken a year ago, and see how that disease has progressed so you can treat it.
Brian Colao: Well, that's something relatively new, I think. I want you to tell me. You know, at the beginning when I would talk to people from Pearl about how it works, you know, in real time, you'd sit in the dental chair. They would take the X-ray, Pearl would overlay, and just based on where you are at that moment in time, it would tell you what's going on. But now I understand it can retroactively go back through other X-rays and other things, even people that are not, if I'm remembering correctly, in the chair that day, it can go back and look at them and you can recall them. You can get on the phone and say, "Hey, you came here a year ago or six months ago and come to think of it, it looks like there's an early stage cavity and we want you to come back in," or something like that.
McKenzie Fagan: you nailed it. So we've been able to look historically for years. I mean, typically, we don't go any more than 18 months in the past. It just becomes clinically insignificant, but up to your provider. That's why it's their choice to decide how far they wanna look back. But where this becomes really interesting is from an operational perspective. You now get to see the beginning of the funnel, if you will. If you're a DSO operator, before Pearl, you were only looking at really what you got in your practice management system in terms of data. That's where that was the heart of your business, right? And anything that's in your practice management system is dependent on a human to enter in a patient's details, enter in the information into the chart to know what needs to be treated. That's all the reason why we're here and why we practice dentistry. Pearl is the first tool that allows operators to understand the very top of that funnel. What are the total amount of opportunities? We call them dental opportunities. Think about any type of treatment plan that you would need for a patient. What's the total amount within each practice? And then it becomes really fun when you talk about operationalizing that data, which we'll talk about in minute here.
Brian Colao: All right. Now,
McKenzie Fagan: Mm-hmm.
Brian Colao: This is the part of the show. Now, he's my technology expert and he does a deep dive and looks into all this stuff as we get ready for each segment. What do you think of this? Or ask your questions.
McKenzie Fagan: I'm actually gonna pivot because I've learned one thing about dental, and I actually went back and audited all of my LinkedIn posts and newsletter articles and all the stuff from the last year. And what I learned is that this industry, as you guys know, you just got a Connector Award, is all about the people. So I'm interested in asking you a question about you 'cause Pearl's been around since 2019. You were not with Pearl and now you are.
Matt McGaw: I'm curious your thoughts on the early days of AI, looking at Pearl come into the market, you know, what you saw and maybe why you made the switch to doing what you do now, 'cause I think the... overall, this industry loves to hear about the people behind it. I'm just... you're, you're, you're a person behind it that people... a lot of people know, so I think it'd be interesting to hear that story.
McKenzie Fagan: Sure. I'm really passionate about this. I came to Pearl for a very specific reason, which I'll walk you through. But your, your original question was what was Pearl in 2019, how did it evolve, and really how... why did I decide to dedicate my career to Pearl and what we're doing here? Well, back in 2019, the word AI was not as common. ChatGPT wasn't around yet. Obviously, pre-COVID. It was a relatively new idea. Pearl was the very first diagnostic or dental diagnostic AI tool to get its FDA clearance. We're now, by the way, the first to receive both 2D and 3D FDA clearance. We have over 25 clearances at this point.
Brian Colao: Is, 3D out yet? I'm just curious. I don't mean to interrupt.
Speaker 4: Yeah.
McKenzie Fagan: It's out. We... we're we're in the middle. It's very complex. I don't wanna talk too much about that as you can
Brian Colao: All right.
McKenzie Fagan: but we have it with quite a few DSOs right now in a very small controlled environment. I expect it to be released to the general public by summertime.
Brian Colao: All right. Well, we'll talk about that later, but Matt was making a good point. You had an amazingly successful career in the DSO industry. I followed you for a long time, but you decided to join Pearl, and you were telling us about
McKenzie Fagan: Yeah. This is the future. This is where we're going. One of my favorite quotes that I've ever heard is, "AI is not coming to take your job, but someone who's using AI will." And so, I really made it my mission to understand where is this technology evolving, where is it going. Before I was at Pearl, I was director of sales... of enterprise sales at Henry Schein One one of the largest digital technology platform companies in the space, and we really specialize in practice management systems. I think that in the old world or even where we are today, we're reliant on what the practice management system gives you in terms of that's how you manage not only your patients, but your schedule, even your employees to some degree. We're really shifting to a different world, where instead of going to your practice management system, pulling up some dashboard that used to be the most amazing thing, we're now going to be interacting with software in a very different way, very specialized to the operator, the person using the system, and it's only... it all starts with the clinical radiologic tool because that is the beginning, that's the foundation, and I truly believe that's going to be the most important piece of how, employees and patients interact with their dentist in the f-... of the future.
Matt McGaw: Do you see, like like an end-to-end system, where Pearl is, is that beginning and also the end, like working through a complete ecosystem of sorts, if that makes sense? Like, 'cause I, I feel like you've got access to some of the most important data and just taking Pearl and almost being like an operating system of sorts, is that your take and also Pearl's take on things?
McKenzie Fagan: Yeah. One thing that we haven't talked about is the insurance game, right? So clinical diagnostic tools are incredibly helpful because obviously you're being more consistent across DSO, but even just more consistent in your diagnosis, whether you're a private practice or a, you know, growing conglomerate or large DSO. But where it becomes really interesting is once you have the clinical clarity that AI brings you, you're no longer fighting with insurance. It's... Insurance company understands and has more clarity about what you're submitting, so the pay cycle becomes so much shorter when you use a tool like this. So when you talk about end-to-end, it's not just the clinical side. It eventually connects into impacting clean claims or even submission rates, acceptance rates which can have a major impact on these organizations.
Matt McGaw: Enterprise value, like all those things, right?
Brian Colao: Well, what you're doing is you're adding an element of objectivity to something for 100 years that has been subjective. You know, the first part that was subjective, it seems to me, is the patient in the chair. You know, the dentist pointing to some black and white ... that you can't really decipher. It looks like ghosts on Halloween or something, and you can't really figure it out, and as the patient, you're not empowered in any way. You're just sort of at the mercy of just sitting there and trying to understand what's being told to you. So that's first element of subjectivity that now you're adding objectivity to with the pink dot over it, and then you're adding a further element of objectivity to insurance claim review process. Remember the battle of the experts? It's like, "Our expert says it isn't a cavity. I say it is." And it goes back and forth and it, you know, often ends up in, you know, nasty disputes and holdup of funds that, you know, that you should have or recoupment of funds. But now, if you're like, "Look, the AI caught it. It's right there. It's documented." it becomes very difficult for the insurance company to, you know, like you said, clean claims. It becomes very, very difficult, you know, for them to contest it. And adds... so it adds sort of an element of objectivity to, one, the insurance audit process and also to the patient experience process as to whether there's something, you know, there or, or not something there that needs to be addressed. And it also allows we haven't talked about this, but for, for example, another company, we're gonna have them on here another time, Curadot, it ... allows sort of interplay between, if you do notice a very, very early stage lesion, and that's exactly what happened to me on my trip to the
Matt McGaw: I saw it. it.
Brian Colao: ... McKenzie knows that. We found an early stage They treated it with Curadont and then came back three months later and it was gone. I I think it's an overall better patient experience, is what it seems to me, McKenzie.
McKenzie Fagan: absolutely. I'm gonna comment on from the DSO's perspective and from the patient's perspective on what you just mentioned.
Matt McGaw: Do you actually comment on the operations teams and, like, everybody involved too? Sorry to interrupt you.
McKenzie Fagan: Sure. I'll get all four.
Matt McGaw: Like, everybody.
McKenzie Fagan: So I, I just got off the phone with a ... they're about a 650 location DSO. They're using Pearl and a subset and rolling it out to the larger enterprise. Just in January alone, they combined Curadont with using Pearl to detect incipient lesions, which is early stage decay. They added $50,000 worth of treatment that was completed, done and finished just in one month piloting Curadont in a very small set of offices. So when you're a, a DSO talking about, you know, increasing same store growth, there is no faster, simpler way than just by providing quality diagnostic care and also a, a procedure like Curadont that's non-invasive. It's effectively a paste that you can wipe on the tooth to restore early stage decay. Every patient doesn't wanna drill, right? They would way rather do something that helps them to restore the tooth rather than having to replace it all together. And Pearl and Curadont could not be a better combination to do so. It's also really impactful because it's hard to see early stage lesions. That's why they're early stage. Sure any ... I mean, I'm not a clinician, however, I've worked with clinicians for better part of last 10 years. We all miss things. We're all busy. And I think early on when Pearl came out, there was this almost like fear, like, "Oh, dentists don't want the big brother. They don't want someone telling them what to do." that's really gone away, and it's now become a clinical supportive tool. It's why it's called second opinion. So now a doctor, in combination with Pearl, can have Pearl up with the pink dot showing this very early stage cavity, and now they have the clinical autonomy to decide, is Curadont the right procedure here? Do we wanna keep it as a watch tooth, or is it potentially something greater that we need to address now?
Matt McGaw: McKenzie, this feels like an every office kind of
McKenzie Fagan: Absolutely.
Matt McGaw: ... at this point. Reminds me of the early days of scanners, digital impression scanners. They weren't very good, maybe at first. And I'm not saying Pearl wasn't very good at first, but you get what I'm saying. Now it all sort of feels like an every office kind of thing to have with a major impact, not just to the clinical teams, to, like, all stakeholders involved. I, I think you probably agree with that, right? it ... The other question is around, like, key stakeholders is interesting to me. Meeting at a DSO, you have all the different levels of individuals that this can affect, and the decision-making process is probably a pain to you in some having to have so many different types of conversations, but maybe can you talk to, to those two comments?
McKenzie Fagan: Sure. So at first, does this affect every practice? Absolutely. We, we've talked about, you know, early stage decay or cavities, but we also detect implant opportunities, periapical radiolucencies. If you're looking at bringing specialty into your practice, you wanna find out which are your endo patients. There's a lot of different ways that you can use these clinical tools to decide what line of business you might wanna open or if you wanna bring in a certain specialist. But does this apply to every practice? 100%. We're actually cleared in over 120 countries. So we have team members all around the world, even though we're only six and a half years old. So that, that took a lot of work. But, you know, we don't just get our teeth cleaned here in America too. So there's every we ... I mean, our mission is to elevate the standard of care for billions of patients worldwide. So that's a really big piece of it. But your second question was, how does this impact other people within the practice that aren't the clinician? Is that your question?
Matt McGaw: Just everybody. I think it's an interesting dialogue, right? The conversation you have with, with the CEO of a DSO compared to a COO compared to a CFO compared to a, a partner doctor, associate doctor, you know, the, the the assistants looking at the images, right? Like, it, it's just such a multi-level conversation. You're touching so many parts.
McKenzie Fagan: Absolutely.
Matt McGaw: Ultimately, the end goal is the, is the patient experience and making sure they have the best care. I, I just think it's interesting to think about the dynamics that you're up against when you're having this conversation.
McKenzie Fagan: Yeah. It all starts with treating the patient ethically and accurately. If you start there, everything else will fall into place. The reality was before Pearl, we had no way to measure that or make it objective. So you had to just rely on your team, which is great, but this is where AI becomes so incredible for our universe, right? Is you're now able to use this tool to proactively measure and figure out what's, what's your next step gonna be? So once we start with accurate care for every patient, now let's think about the different dynamics within a DSO. Well, if you're a CEO, one, when you implement Pearl, you know that immediately right off the bat with relatively no friction because it's integrated into your imaging system today, it's one of the few tools that you can implement and start to see results within one single day.
Brian Colao: Well, so stop on that.
Matt McGaw: Mm-hmm.
Brian Colao: very important. I'm I like what you're saying about the results in one day. But first, that you said integration. Are, are you
McKenzie Fagan: Yeah.
Brian Colao: with everything? Or I wanna talk about it.
McKenzie Fagan: I think we're at over 35 imaging systems 20 different practice management systems worldwide. So yes.
Brian Colao: Well, well, that's a question I
McKenzie Fagan: we integrate with.
Brian Colao: We always ask that question
McKenzie Fagan: Yes.
Brian Colao: because one of the biggest obstacles to adaptation of new technology solutions is lack of integration.
McKenzie Fagan: Absolutely.
Brian Colao: I always stop sort of right there. So Pearl is integrated with virtually everything out there?
McKenzie Fagan: Mm-hmm.We also work with a lot of DSOs that maybe haven't centralized their practice management or imaging systems yet. Maybe they acquired a bunch of different practices for different reasons. Pearl then can become that standardization tool. Because we integrate with all the different imaging practice management systems, Pearl's dashboard and data center basically allows you to have a top-down, org-level view of all of your offices in one place.
Brian Colao: Even if they use multiple PMMs?
McKenzie Fagan: Even if they use different practice management or imaging systems.
Brian Colao: Now, the point you are making is one that I've covered a lot when we talk about diagnostic AI, and I think you were saying, you turn this thing on, and literally on day one... And and I wanna emphasize this, it's an ethical way to do more
McKenzie Fagan: Yes.
Brian Colao: ... you know, increase your revenue, increase your EBITDA, increase your enterprise value. Obviously, when people say, "Oh, this is gonna make us do more cases," sometimes people get a little cringy. But this is an ethical way to do this, because again, the AI is only objectively gonna catch things that are medically necessary.
McKenzie Fagan: You're exactly right. And I also say that the AI can help you from doing procedures that you shouldn't be doing, right? There's the opposite way of looking at this because Pearl will tell you how far the disease has progressed and then it's up to the doctor to make that clinical decision. But how often are... I mean, do how many claims are written off a month on average for a private practice or a DSO? it's significant, right? So if you can ensure that every claim that you're sending has the clinical proof behind it, you're only decreasing that amount of time of the payment cycle and the insurance cycle from the time you submit the claim to you're actually getting paid, because there's less need for that clinical review. Sure, if you don't know this, for an insurance company to deny a claim, it actually has to be a licensed clinician to deny that claim. They cannot use any tool to just go and say they're going to deny you. It has to be reviewed. That's expensive. That takes time. That's expensive for the insurance company and for the DSO. So using clinical AI when you submit those claims is actually a benefit for all.
Matt McGaw: A question that... Remember, I did send a doc over to you for a five-location DSO at one point, and he just called me up and said, "Which one and why?" Like, "They all seem pretty much the same." And he wanted to know which one, and obviously, I sent him towards you. But just in general for the people watching, like if they feel that all of 'em are very similar that are on the market now, like why are you the differentiator, and what is your differentiator?
McKenzie Fagan: Yeah. No, great question. I get asked all the time and happy to answer it here. It's there's a reason why Pearl is the largest global footprint of any of the radiologic AI companies. And it's for a couple of different reasons. We are a provider-first organization. What that means is we have always and will continue to support providers and ensuring that not only everything we just talked about, everything is clinically accurate, but that they are supported when they need to send or present anything to an insurance company. That is very different than the other AI companies that are out there. We will always support the providers. That is where we believe is the most important and ethical way to approach the AI game, if you will, over the next few years. But also when you look at just the details, that's really more of our foundation and what we're doing. But if you're asking me, like, "Technically, what are the difference between the different companies?" Pearl is the only integrated clinical AI tool that integrates not only with the imaging system, but also with the practice management system. So we also have a AI-guided schedule view, where not only can we show you where there are patients that are coming in for that day that maybe have undiagnosed treatment that you should look at, but also suggest where in the schedule you might be able to move them or move someone around so that you can maximize your day. Pearl is a very operational-led platform as
Matt McGaw: That's important.
McKenzie Fagan: It's
Matt McGaw: I'm not sure I knew that.
McKenzie Fagan: different.
Matt McGaw: I don't feel
Brian Colao: I'm not sure I knew that either. So can you expand a little bit on that part of it?
McKenzie Fagan: Sure. So they probably all sound similar because you're just thinking of X-rays and colors on an X-ray. And sure, if that's all you're evaluating, you're using 2% of the value behind it, I'm glad you're getting that 2%. But what goes beyond that is how it all integrates together. I think I heard you earlier on your show saying that there's so many different AI platforms out there. Do you want a different insurance verification tool, a clinical AI tool and everything else to manage your system? Or do you want it all in one place? What Pearl does uniquely is not only do we offer clinical insights natively to your X-ray system, this is what we all talked about, this is the radiologic AI solution, but we also embed all the way throughout the practice management system, highlighting different opportunities in the schedule, whether you have a patient that's coming in today that maybe has an implant opportunity that has never been discussed or never been treatment-planned. But we also able to verify their insurance before the patient comes in. So this means when you use the Pearl AI platform, you're you're able to see what patients are coming in, what hasn't been diagnosed, and of everything they're coming in for, what are they eligible for? Because we all know with, sure, even personally, when you decide what your going, you know, to do with your dentist, it is a partial financial discussion. And that's where Pearl is very... ... very different, is we offer very comprehensive, very detailed insurance breakdowns that integrate with that schedule.
Brian Colao: Well, that's very, very interesting. So it will embed in all aspects of the PMS system as, as opposed to maybe just the X-ray portion is what you're saying. And I'm not sure I knew that, Matt.
Matt McGaw: That's really
Speaker 4: Yeah.
Brian Colao: So, you know, if somebody's coming in and the Pearl's review of the X-ray indicates potentially an implant opportunity, it will note that. And what will it do? It'll note maybe a point in the schedule where you could potentially schedule an implant or something like that?
McKenzie Fagan: Yeah. Our in Pearl's platform, we actually, we call it the daily huddle. So it's the AI-powered daily huddle. Doctors are really used to doing this on a daily basis.
Brian Colao: Right.
McKenzie Fagan: they come in, in the morning, they look at their schedule. Pearl will show well, what you can see in the practice management system is scheduled treatment and unscheduled
Brian Colao: Right.
McKenzie Fagan: that patient by the hour. Pearl adds another column, AI predicted opportunities for those patients. What did Pearl detect that hasn't been added to the treatment plan? That hasn't been diagnosed? So if you're a doctor working for a DSO you could go into Pearl's schedule and filter to just see your patients that are coming in for that day and how many of your patients have undiagnosed treatment opportunities or, obviously, if they're not diagnosed, they're not scheduled. This is where you unlock the most potential, because your patients are already coming in. You didn't spend a dollar on marketing to get that patient in the door. They're already your patients. So not only are you presenting a fully comprehensive treatment plan, but you're making sure nothing goes un-missed, or goes missed.
Brian Colao: Yeah, I mean, something we talk a lot about on this show is, you know, compliance. And, you know, as a, I think I'm in my 31st year of being an attorney, I, I wanna just confirm a couple things to anybody, and you can agree with me or not. But Pearl doesn't have a dental license, cannot practice dentistry. The dentist has you know, in an extreme case, can ignore it completely if they want to. They're not obligated to utilize it, but it's, it's supposed to be a second set of eyes and with
McKenzie Fagan: That's why the product is called Second OpinionĀ®.
Brian Colao: Well, that, you did say that I walked into that one.
McKenzie Fagan: Yeah.
Brian Colao: But, but yes, it's, it's sort of a second set of eyes. But, you know, the dentist is, as, as we all know, legally responsible from the beginning of the case to the end of the case. Pearl in no way changes that, but it gives them sort of, I guess, like you said, a second set of eyes or a second reviewer to help them finalize what their diagnosis is gonna be in that situation.
McKenzie Fagan: Yeah, exactly.
Brian Colao: And in terms of compliance, I assume you can tell us for everybody why it's HIPAA compliant.
McKenzie Fagan: Absolutely.
Brian Colao: Right. And you, you have FDA clearances, you do?
McKenzie Fagan: Over 25.
Matt McGaw: We could have a whole show on compliance. That'll
Brian Colao: No we're not gonna do that here. That will bore everybody. Nobody will tune in for that show. But I just wanna make sure, when people watch this, they have the comfort of knowing you thought of compliance and at least you believe it to be compliant, you also believe it to be HIPAA compliant, you said, correct?
McKenzie Fagan: Yes, We wouldn't be here without it. That's incredibly important. I actually had one doctor, and he's the he's the chief clinical officer of a very large DSO that's been using Pearl for quite some time now. He actually called me and said, "McKenzie, when do you think it's going to become a compliance issue to not have clinical AI?"
Matt McGaw: Mm-hmm.
Brian Colao: There were some panels. You know, I, I was recently, like you said, I came back from the conference where the the CareStack Conference, they gave me that, that connector award, but it was technology was a big focus of that. And there were, you know, some issues raised at that conference recently about, you know, when is it going to be the standard of care? I got those questions sometimes on my panel. But, you know, the Dental Board move very, very slowly. The ADA moves very, very slowly. And, you know, you're gonna need to see some type of, you know, recommendations from dental boards possibly. The ADA may, in the future, make a statement on this, and that, that's gonna take some time. So I don't expect, you know, the standard of care to, you know, evolve, you know, in the next year or two. But that doesn't mean, at least to if there's a technology out there that enhances the patient experience and proves it makes it superior, we can't use it.
McKenzie Fagan: Absolutely. Ada has invested in Pearl, so clearly, I mean, we're, we're very close. We work frequently to make sure that we're only improving the standard of care. So it's, it's there.
Matt McGaw: Do we have any idea what the percentage of private practice or DSOs like actually have implemented AI within
Brian Colao: Diagnostic.
Matt McGaw: diagnostic area?
McKenzie Fagan: It's improving rapidly, as you can imagine.
Matt McGaw: what's
McKenzie Fagan: 2025 was the fastest adoption year. It, it would be, it would be a guesstimate, but I think we're about 25% of the market share or of the market has adopted clinical AI tools. I think that will only compound over the next few years.
Brian Colao: All right. Let's talk for a few minutes 'cause I talk a lot about this, what are the obstacles to implementation or adaptation? And if you could tell us, McKenzie, you know, what has worked really well and when somebody, you know, says, you know, "Gee, we weren't able to implement this," or, "It didn't go well," why does that happen and how do you, you know, prevent that from happening or?
McKenzie Fagan: Great question. So let's take the technology piece of implementation and then the operational people
Brian Colao: Right.
McKenzie Fagan: because they're very different. From a technical perspective, it's actually overnight. It's actually even faster than that. We essentially connect to your imaging and your practice management system. We can sync your historical images overnight, so Pearl's detections are automatically popping up on your X-rays starting the very next day. That is very, very quick. What isn't quick is the adoption and the relearning of how to use a tool like this. So what's worked well was your question. If you're a DSO, or actually let me start at private practice. If you're a private practice, you're a doctor, usually you're the one evaluating, doing the demo. And it's actually probably pretty... it's a lot easier to teach your staff why you're investing in this type of tool to help them be better clinicians themselves. Where it gets challenging as a DSO is whoever's making the decision at the, you know at the C-level your operators might not be working with them on a daily basis. So what we've found is so critical is alignment from the C-suite on why they're investing in this type of technology. We also partner really closely with larger DSOs to create video content to help send out to the remainder their organization of why they're making this decision. We're really excited Pearl's being rolled out at all 1,100-plus Pacific Dental Services locations this year. So we've done a lot to ensure that every single doctor is educated on why they're making this investment and has resources to be trained. But the good news about a clinical tool like this is it doesn't take that long and it's language agnostic. If you see a pink circle on your X-ray, you can kind of figure that's something to look at. It's not like there's this super long comprehensive training program where you gotta shut the office down like you do for a practice management system. It's a tool that you can implement seamlessly. But it gets a lot more fun when you pair it with Curadent and other tools that, you know, you can use to help increase the production numbers.
Brian Colao: So this is a
McKenzie Fagan: Correct.
Brian Colao: product, a SaaS-based one. And I assume, as with other SaaS-based products that we've had on this show, you know, the pricing is gonna depend on how many offices and things like that?
McKenzie Fagan: Yeah. Absolutely. And then of course, the full suite. So, you know, moving forward with the clinical AI tool, as well as the enhanced schedule and insurance verification tools, get a lot sweeter pricing that way. And it's just better for you because you have everything in one platform. But of course, just dependent on number of locations.
Matt McGaw: Is is the big brother thing still a thing?
McKenzie Fagan: Not as much. It it really isn't. I mean, I said this earlier, it's like having spellcheck. I'm educated, but I would never in a million years send an email without having it be rants through spellcheck. I know how to spell, I've got pretty good grammar, but I always wanna make sure I'm not missing anything. And I think that's been adopted across the space.
Brian Colao: I mean, honestly, it can keep some aging practitioners, you know, at a high level for longer. I mean, I know, you know, as older I get, my vision kind of goes downhill. And every time I go, they gotta change the prescription. Thank goodness I'm not looking at X-rays or anything. But, you know, this thing... I mean, to me, it seems like even if, you know, you're aging, your vision's going a little bit or something, you know, it's like you got a spellcheck there to kind of help you operating at a higher level for longer. To me, I've never, when I've spoken to doctors, ever understood the big brother thing. I've really always thought this could be, you know, sort of an an enhancement, you know, to make them better is what I always thought.
McKenzie Fagan: Yeah.
Brian Colao: But
McKenzie Fagan: One thing that we're working on right now that seems to be very interesting, but is not widely adopted across the industry yet, is we're working on automating treatment planning. So what that looks like is Pearl would find the disease and then within... Since the schedule and the clinical tools are all in one place we can actually suggest what are high likelihood treatment plans for the doctor to choose. Of course, the doctor always has the decision, but this helps them be quicker and faster. we all know, doctors are not very good at actually entering their notes and putting in their diagnosis into the odontogram, back into the schedule eventually to be sent for insurance claim. Pearl's helping automate that by giving them suggestions that they can then click, attach the right code, and start the whole claim creation process. So that's really what this is going to look like is automating it from, you know, the very beginning when the patient walks in the door till they leave and you collect an insurance payment.
Brian Colao: All right. I know the suspense is probably killing you. This is the portion of the show, the last couple minutes. Matt's our technology expert. You did a deep dive into Pearl. You've researched this extensively. What's your verdict on it?
Matt McGaw: It's nothing from the deep dive, but what we learned today about the practice management system and having the ability... these are my words, to have what sounds to me like a seamless way for integration to happen so many different levels within practice and DSO. They do not have to really be, like, trained up to understand it and to use it and have it automatically sense, like, what is going to be the right potential opportunity in the practice. And to be honest, this is the DSO, you know, Technology Show too. Profitability is a real thing. you talk about it on stage all the time, Brian, like same-store growth. You cannot buy EBITDA any longer, at least at this time. And it just seems to me having something like this inside of a DSO is a no-brainer. It's just a matter of committing to it, to making sure that it provides that impact for same-store growth. And obviously, you know, down the road, it's always about patient care and patient experience and...
McKenzie Fagan: Yeah.
Matt McGaw: Yeah. Thank you for that information. I don't think I saw that on the website of looking, so it was great.
Brian Colao: All right. So McKenzie, last final word here. If somebody watching this, you know, is interested in learning more about Pearl, either, you know, implementing it in their office or they got questions or they wanna learn about it, how best to do that?
McKenzie Fagan: Feel free to reach out to me directly. I think we'll have my LinkedIn below here. You can reach out to me there. My email is mackenzie@helpearl.com. You can also go straight on to helpearl.com's website and request a demo there.
Brian Colao: Well, thank you so much. This has been the DSO Technology Show. I'm Brian Clayo. I'm here with my co-host Matt McCall and our special guest today was McKenzie Fagan of Pearl. And so great to be with you and stay tuned for new technologies.
Related episodes
Ep 10Post-Dykema Conversation: One Conference. Many Different Takeaways and What’s Next
Brian Colao and Matt McGaw
Ep 9From Manual to Cloud: The Surprising Evolution of Dental Imaging Over the Last Decade
Dustin Johnson and Ryan Chan, SOTA Cloud
Ep 7AI, Adoption, and the Reality of Change Inside DSOs
Ali Hyatt, Henry Schein One
Ep 6The Surprising Truth About AI’s Power to Replace Human Insurance Calls
Parag Javari and Amber Day, VoiceCare AI
Get the next episode
One short email when each episode goes live.